Arrhythmias & electrophysiologyCohort study
Impact of ventricular tachycardia ablation in subcutaneous implantable cardioverter defibrillator carriers: a multicentre, international analysis from the iSUSI project
- Registry-based cohort study
- multicentre
- international
Authors' conclusion
In a real-world registry of S-ICD carriers, the combined study endpoint of arrhythmic events and cardiovascular mortality was lower in the patient cohort undergoing VTA at long-term follow-up.
Study context
- Population
- iSUSI registry subcutaneous ICD (S-ICD) carriers with an implantable cardioverter defibrillator (ICD) shock or hospitalization for monomorphic ventricular tachycardia (VT)of 1661 iSUSI patients
- Participants
- 211 carriers
- Exposure
- VT ablation vs no VT ablation in S-ICD carriers
- VT ablation (VTA)+n = 59
- VTA-n = 152reference
- Outcome
- Composite of:
- Device-related appropriate shocks
- Monomorphic VTs
- CV mortality
Main finding
As reported in the abstract
Adjusted hazard ratio
0.262
CI 0.100–0.681
P = 0.006
Events by group
VTA+
5
events
VTA-
41
events
VTA+ vs VTA-
adjusted HR 0.262 (CI 0.100–0.681); P = 0.006
Observational data: associations, not effects.
Secondary outcomes
CV mortality
P = 0.043
Crude VTA+ 1/59 · VTA- 13/152
Yearly event rate
Original publication
Impact of ventricular tachycardia ablation in subcutaneous implantable cardioverter defibrillator carriers: a multicentre, international analysis from the iSUSI project. Europace. Published 8 April 2024. doi:10.1093/europace/euae066
Summarised from the published abstract; every number is checked against it